

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Vizimpro Prior Authorization Policy

- Vizimpro® (dacomitinib tablets – Pfizer)

REVIEW DATE: 12/11/2024

OVERVIEW

Vizimpro, a tyrosine kinase inhibitor (TKI), is indicated for the first-line treatment of patients with metastatic **non-small cell lung cancer (NSCLC)** with epidermal growth factor receptor (*EGFR*) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.¹

Guidelines

National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (version 11.2024 – October 15, 2024) recommend testing for sensitizing *EGFR* mutations in patients with metastatic disease.² Patients with sensitizing *EGFR* mutations have a significantly better response to the *EGFR* TKIs. The most common *EGFR* mutations are exon 19 deletions and exon 21 (L858R) substitution mutations. Other less common mutations that are also sensitive to *EGFR* TKIs include L861Q, G719X, and S768I; these mutations cumulatively account for approximately 10% of all *EGFR* mutations. NCCN recommends Vizimpro as first-line treatment under “Useful in Certain Circumstances” for patients with advanced or metastatic NSCLC with *EGFR* exon 19 deletions, exon 21 (L858R) substitution mutations (category 1); it is listed under “Other Recommended” first-line therapies for L861Q, G719X, and S768I mutations (category 2A).

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Vizimpro. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Vizimpro is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Non-Small Cell Lung Cancer. Approve for 1 year if the patient meets ALL of the following (A, B, and C):

A) Patient is ≥ 18 years of age; AND

B) Patient has advanced or metastatic disease; AND

C) Patient has sensitizing *EGFR* mutation-positive non-small cell lung cancer as detected by an approved test.

Note: Examples of sensitizing *EGFR* mutation-positive non-small cell lung cancer include the following: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X, and S768I.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Vizimpro is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Vizimpro® tablets [prescribing information]. New York, NY: Pfizer; December 2020.
2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 11.2024 – October 15, 2024) © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 6, 2024.
3. The NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 6, 2024. Search term: dacomitinib.